Proclarix

Leave a review
Bookmark
Share
Report
prev
next

Indicaton

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Therapeutic indications

Diagnostic
Oncology

Type of product

Diagnostic

Table

Phase

Marketed
Available in

EU, Switzerland

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, mRNA and other mRNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

SOT201 (Immunocytokine, PD-1 x IL-15)

solid tumors

Phase I started

SOT109 (Antibody-Drug Conjugate)

solid tumors, mainly colorectal